Skip to main content
OpenTrials
Completed

NCT Number: NCT01328457

An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh

The purpose of this study is to evaluate the effectiveness of treatment with PMIM in patients with visceral leishmaniasis within the VL-endemic region of Bangladesh at EOT (21/22 days after treatment begins), and at 6 months after end of treatment (Day 202/203, -15 to +30 days).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Visceral Leishmaniasis Behavior Chemically-Induced Disorders Drug-Related Side Effects and Adverse Reactions Euglenozoa Infections Health Behavior Infections Leishmaniasis Leishmaniasis, Visceral Medication Adherence Parasitic Diseases Patient Acceptance of Health Care Patient Compliance Protozoan Infections Treatment Adherence and Compliance Vector Borne Diseases

Age range

5 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bhaluka Upazila Health Complex, Bhaluka, Mymensingh District, Bangladesh

Loading trial locations.

About this study

Safe, effective and affordable treatments for visceral leishmaniasis (VL) that are widely available to the poorest populations are urgently needed in Bangladesh in areas where the disease is endemic. Paromomycin IM Injection (PMIM) was approved for the treatment of VL in August 2006 by the Drugs Controller General of India (DCGI), and it offers an attractive alternative to treatments that are currently available.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signs and symptoms of VL including:
  • History of intermittent fever for at least two weeks
  • History of weight loss and/or decrease in appetite
  • Enlarged spleen
  • VL serologically confirmed using the rK39 test:
  • Willingness / ability to understand and provide informed consent prior to participation in this study:
  • Age ≥ five years and ≤ 55 years, and weighing at least five kg
  • Adequately hydrated as assessed by clinical criteria and able to maintain adequate hydration on an outpatient basis through oral intake of fluids
  • Clinically stable and appropriate for treatment with PMIM as an outpatient, if possible (subjects may be hospitalized to receive 21-day dosing at the discretion of the investigator)
  • Living in the VL-endemic areas in Bangladesh

Exclusion criteria

  • Active tuberculosis or taking anti-tuberculosis medications
  • Previous treatment with Paromomycin IM Injection (PMIM)
  • Clinically significant severe anemia as determined by the investigator
  • Clinically significant renal or hepatic dysfunction as determined by the investigator, or history of clinically significant renal or hepatic dysfunction
  • History of Hepatitis B or C; or known HIV positive
  • History of hearing loss
  • Other serious illness or medical condition that, in the opinion of the doctor, would interfere with the patient's ability to receive PMIM treatment or comply with the study procedures, or that could obscure toxicity of or response to PMIM
  • Major surgery within 30 days prior to first dose of PMIM
  • History of hypersensitivity to aminoglycosides or to any of the components of PMIM, including sulfite
  • Any history of VL or treatment of VL at any time
  • Patients who have received any investigational (unlicensed) drug within the last six months
  • Concomitant use of other aminoglycosides (e.g., gentamicin, tobramycin, amikacin), nephrotoxic and ototoxic drugs, or immunosuppressive drugs
  • Proteinuria (results > 1+ ) on urine dipstick analysis at screening visit and/or
  • Serum creatinine above the upper limit of normal (ie, serum creatinine >1.1 mg/dl in males and >0.9 mg/dl in females
  • Pregnant or lactating women

Treatment and study plan

Paromomycin sulfate

Drug

Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).

Other names: aminosidin sulfate, aminosidine sulfate, monomycin A sulfate, amminosidin sulfate, catenulin sulfate, crestomycin sulfate, estomycin sulfate, hydroxymycin sulfate, neomycin E sulfate, paucimycin sulfate, Humatin®, Gabbromicina®, Gabromicina®, Gabromycin®, Gabboral®, Kapseal®, Pargonyl

Primary outcomes

  1. Final cure rate

    Time frame: 6 months after end of treatment (Day 202/203, -15 to +30 days)

    Criteria evaluated (binary fashion):

    • Patient's temperature less than 99.4°F in clinic at EOT visit? (Y/N)
    • Patient reported resolution of fever and NO fever within the last 5 days? (Y/N)
    • Spleen size decreased from screening value? (Y/N)
    • Is the clinical impression of the treating physician that of an adequate clinical response? (Y/N)

    The patient is deemed to have achieved final cure if answers to a, b, c, AND d are all "Yes" OR if one answer (a, b, or c) is "No" but all others and "d" are "Yes". In addition, the clinician will inquire about pregnancy status for female patients.

Secondary outcomes

  1. Initial clinical response rate

    Time frame: End of treatment (21/22 days after treatment begins)

    Criteria evaluated (binary fashion):

    • Patient's temperature less than 99.4°F in clinic at EOT visit? (Y/N)
    • Patient reported resolution of fever / NO fever within the last 5 days? (Y/N)
    • Spleen size decreased from screening value? (Y/N)
    • Is clinical impression of the treating physician that of an adequate clinical response? (Y/N)

    The patient is deemed to achieve an initial clinical response if answers to a, b, c, AND d are all "Yes" OR if one answer (a, b, or c) is "No" but all others and "d" are "Yes". Also, the clinician will inquire re: pregnancy status for female patients.

  2. Patient compliance with PMIM treatment

    Time frame: 22 days

    Proportion of patients complying with prescribed 21 daily injections over no more than 22 days.

  3. Safety of PMIM in the study population based on clinical assessment by the study physician at the Upazilla Health Centre.

    Time frame: 6 months after end of treatment

    All serious adverse events (SAEs), regardless of causality, from time of first administration of PMIM through 30 days post-EOT.

    All adverse events (AEs), regardless of causality, from time of first dose through 30 days post-EOT.

    Vital signs on Study Days 1 to 21/22 (or early termination), any unscheduled visit after EOT, 30 days after EOT, and 6 months after EOT.

    Patients who become pregnant during treatment/within 30d following EOT will be included in the safety population. Offspring from pregnancies will be followed for safety under a separate study for a period up to 3 yrs after birth.

  4. To introduce PMIM in government health facilities in rural Bangladesh.

    Time frame: October 2011

    Training study staff to provide treatment with PMIM at selected Upazila level health complexes in rural Bangladesh.

Sponsors and collaborators

Lead sponsor

PATH

Other

Collaborators

  • GVK Biosciences
  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • Shaheed Suhrawardy Medical College and Hospital

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2012
First posted
Apr 4, 2011
Registry last updated
Apr 4, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.